"The entire Part D and
Managed Medicaid pharmacy management industry would have to change. Prime, and
other PBMs, will need to develop new tools and methods to continue to negotiate
price on behalf of millions of members."
— Mike Kolar, Prime Therapeutics, LLC's senior vice president
and general counsel, spoke with AIS's RADAR
on Drug Benefits about the impact of the Trump administration's
proposed rule that would eliminate safe-harbor protections on drug
rebates.
No comments:
Post a Comment